Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026
Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb) autoinjector is now available in the United States for initiation and maintenance treatment of early Alzheimer’s disease, expanding the company’s focus on making anti-amyloid therapy more accessible and convenient. The availability of the once-weekly subcutaneous autoinjector provides an alternative to intravenous administration for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, allowing treatment to begin with an at-home administration option. LEQEMBI IQLIK is designed to reduce dependence on clinic-based IV treatment while giving patients and care partners greater flexibility throughout the treatment journey
LEQEMBI IQLIK Expands At-Home Treatment Option
The newly available formulation represents an important development in the delivery of Alzheimer’s disease therapy, particularly because the autoinjector can be used from treatment initiation rather than only after an initial period of IV therapy. The approved initiation regimen is 500 mg once weekly, administered as two consecutive 250 mg injections, with each injection delivered in approximately 15 seconds. After 18 months of IV or subcutaneous treatment, LEQEMBI IQLIK may be used for maintenance dosing at 360 mg once weekly. Patients can also switch between IV and subcutaneous administration, providing additional flexibility based on treatment needs and preferences. For cGxP.wire readers, the development is particularly relevant because it demonstrates how drug-delivery technology and pharmaceutical innovation are increasingly being integrated into treatment pathways to potentially reduce administration burden and improve continuity of care.
At-Home Administration Could Reduce IV Treatment Burden
According to Eisai and Biogen, the availability of subcutaneous LEQEMBI administration could reduce the time patients spend receiving anti-amyloid therapy through IV infusions and may lessen some healthcare resources associated with infusion preparation and monitoring. At-home dosing may also make it easier for patients and care partners to maintain treatment schedules while traveling or managing daily activities. The companies are providing implementation resources including an Instructions for Use video, IQLIK Welcome Kit, treatment tracker, injection reminder tools and demonstration materials. Healthcare providers will also have access to electronic health record support and a step-by-step treatment initiation guide. However, the move to at-home administration does not remove the need for clinical monitoring. Brain MRI remains an important part of treatment management because of the risk of amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapies.
Advertisement
Clinical Evidence and Safety Remain Central to Use
LEQEMBI’s U.S. availability is supported by clinical evidence from the Phase 3 Clarity AD study, which evaluated 1,795 patients with early Alzheimer’s disease and demonstrated a statistically significant slowing of disease progression compared with placebo. The companies reported that IV lecanemab slowed progression by 27% at 18 months on the Clinical Dementia Rating-Sum of Boxes endpoint. At the same time, the treatment carries important safety considerations, particularly ARIA-E and ARIA-H, which can involve brain edema, microhemorrhages or other bleeding-related abnormalities. The prescribing information includes a boxed warning and recommends baseline and periodic MRI monitoring. Risk can be higher in patients who are ApoE ε4 homozygotes, making appropriate assessment and monitoring important during treatment. The availability of LEQEMBI IQLIK therefore represents not simply a shift from hospital-based infusion to at-home injection, but a broader change in the practical delivery of an established disease-modifying Alzheimer’s therapy, with convenience balanced against the need for continued specialist oversight and safety monitoring.
Source:Eisai press relese
